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Abstract
The aim of this study was to evaluate the use of serum type II collagen cleavage epitope
and serum hyaluronic acid as biomarkers for treatment monitoring in osteoarthritic dogs.
For this purpose, a treatment model based on mesenchymal stem cells derived from adi-
pose tissue combined with plasma rich in growth factors was used. This clinical study
included 10 dogs with hip osteoarthritis. Both analytes were measured in serum at baseline,
just before applying the treatment, and 1, 3, and 6 months after treatment. These results
were compared with those obtained from force plate analysis using the same animals during
the same study period. Levels of type II collagen cleavage epitope decreased and those of
hyaluronic acid increased with clinical improvement objectively verified via force plate anal-
ysis, suggesting these two biomarkers could be effective as indicators of clinical develop-
ment of joint disease in dogs.
Introduction
Osteoarthritis (OA) affects the articular cartilage in both human [1] and veterinary patients
[2], making its treatment challenging for investigators and clinicians.
Alterations in articular cartilage depend on the balance between the synthesis and degrada-
tion of the cartilage matrix. These variations could be monitored by measuring the molecules
(biological markers) derived from this synthesis and degradation, which are released in biologi-
cal fluids [3]. In this sense, synovial, serum and/or urinary assays of bone and cartilage markers
are becoming less invasive alternatives to osteochondral biopsy for assessing the response of
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the articular components to disease and injury [4]. Biomarkers could be useful not only for the
diagnosis and early detection of disease, but also for treatment monitoring, because radio-
graphic diagnosis is not entirely conclusive due to its low sensitivity to detect small changes in
the initial stages of pathology [5]. At this time, a biomarker, or combination of biomarkers, as a
tool for the evaluation of OA has not been fully established, but because it is a simple process
that is associated with low cost, easy collection, and short examination time relative to other
methods, studies are contributing to establish a full methodology for the diagnosis and moni-
toring of this disease based on biomarkers [6].
Most of the biomarkers used in joint disease are articular cartilage components such as
chondroitin sulphate (CS), keratan sulphate (KS), hyaluronic acid (HA), or type II collagen,
among others. Because they are articular cartilage components, some of these biomarkers,
alone or together, could have the potential to provide clinically useful indices of the effects of
isolated joint injury, the progression of joint changes, and/or the response to therapy [7].
Type II collagen is the major structural protein of cartilage and accounts for approximately
50% of the extracellular cartilage matrix. Fragments derived from collagen degradation have
been investigated as potential markers for remodeling cartilage pathologies such as OA [8].
Among the wide variety of type II collagen degradation products, a neoepitope in type II colla-
gen that is generated by the intrahelical cleavage of collagenases (C2C) has been well studied in
vivo [9]. However, few studies have been developed about C2C concentration as a diagnostic
tool in OA dogs, in which synovial fluid [10,11] and serum [4,12] levels of C2C seem to be sig-
nificantly increased.
Another major component of synovial fluid and the extracellular matrix, HA is a high
molecular weight glycosaminoglycan synthesized by chondrocytes and synovial fibroblasts.
Some studies [6,13] have shown that HA levels in serum are increased in human patients with
OA, and that this increase is considered a reliable biomarker reflective of cartilage damage and
synovitis in these patients. However, in the dog, conflicting results have been reported: some
authors showed similar results as in humans [14,15], and others reported that HA levels in
dogs seem to decrease [16] or remain invariable [17] when OA is present. Furthermore, recent
studies relied on a clinically subjective scoring system to demonstrate an increase in HA serum
levels coinciding with improved clinical condition in OA dogs [18,19].
In human patients, a direct correlation between C2C, HA levels, and OA pain has been
demonstrated [13]; however, in the literature there are no studies correlating serum levels of
biomarkers such as HA or C2C with objective evolution of symptoms of OA in dogs, mainly
because in domestic animals, quantification of pain is difficult to achieve.
In the past 5 years, the use of mesenchymal stem cell-based (MSC) therapies and plasma
rich in growth factors (PRGF) for repair and regeneration in OA has become a new avenue of
treatment as an alternative to surgery [20, 21]. The hypothesis of this study was that serum
C2C and HA could serve as objective biomarkers in order to evaluate the effectiveness of OA
treatment in dogs. For this reason, the aim of this work was to serially measure these biomark-
ers at different times in OA dogs treated with a combination of MSC and PRGF, and evaluate
these measurements in relation to functional status measured by a kinetic force platform.
Materials and Methods
Animals
Ten client-owned, presa canario dogs with moderate to severe OA associated to hip dysplasia
were enrolled for inclusion in this study. The body weight of enrolled dogs ranged from 47 to
58.3 kg, and ages were 3 to 7 years. Radiographs confirmed the presence of bilateral OA com-
patible with D and E degrees of hip dysplasia as defined by the Fédération Cynologique
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Internationale [World Canine Organization]. Dogs with D degree dysplasia showed obvious
deviation from the norm, with evidence of a shallow acetabulum, flattened femoral head, poor
joint congruency, and in some cases, subluxation with marked changes of the femoral head
and neck. The E-degree dysplasic dogs showed complete dislocation of the hip and severe flat-
tening of the acetabulum and femoral head [22]. Additional radiographs of knee and elbow
joints were taken in order to ensure that hip OA was the unique reason for the observed clinical
signs. A complete clinical evaluation (physical examination, including vital signs and neuro-
logic and orthopedic exams) assured that general health was otherwise normal. In addition,
basic hematology and blood biochemistry parameters were obtained prior to and after the
study in order to determine if treatment had non-desirable systemic effects.
The research protocol was revised and authorized by the Ethical Committee of Animal Wel-
fare (CEBA) of the University of Las Palmas de Gran Canaria. The owners of each animal gave
permission and signed a written consent form.
Adipose tissue biopsy and culture of MSCs
A 120-mL blood sample was obtained under aseptic conditions and processed with the Dog-
Stem kit (Vet-stem, Biopharma, Belgium), and then, under general anesthesia with 3% sevo-
flurane, a biopsy of 20 g subcutaneous fat tissue from the inguinal region was obtained through
a surgical incision. Immediately, the fat biopsy and blood were sent at 4°C for cell isolation and
amplification to the Fat-Stem Laboratory (Belgium). The adipose tissue was processed accord-
ing to standardized Fat-Stem Laboratory procedures and in accordance with good manufactur-
ing practices (GMP) laboratory regulations. Briefly, the derived adipose tissue was digested
enzymatically, washed and centrifuged several times to obtain a concentrate of cells. Subse-
quently, the mixture of cells was grown in a bioreactor environment with controlled tempera-
ture, oxygen, and CO2 control. After cultivation in several media, the following parameters
were assessed in the cells in order to evaluate the quality of the treatment: fibroblastic morphol-
ogy (spindle shaped); adherence to glass or plastic when cultured; ease of trypsinization; color
of the cultivation media; proliferation time (doubling time) ± 75 hours; presence and absence
of surface antigens that determine cellular identity; capacity to be induced in vitro to differenti-
ate into osteoblasts, chondrocytes, and adipocytes; and viability. These parameters coincide
with the three minimal criteria standards for defining MSCs suggested by the International
Society for Cellular Therapy: adherence to plastic, specific surface antigen expression, and mul-
tipotent differentiation potential [23]. Finally, the cells were expanded, and 2 weeks after
biopsy, 30 million cells were sent for clinical evaluation in two 2-mL tubes containing 15 mil-
lion MSCs per tube [24].
Finally, PRGF was prepared following a previously published method [25]: 20 mL blood
was aseptically collected in four 4.5-mL citrate tubes, and then centrifuged for 8 minutes at 460
× g. Before infiltration, the PRGF was activated with 5% of its volume with 10% calcium chlo-
ride. Then, PRGF was associated to MSCs, and the resulting 4-mL solution was injected asepti-
cally into both hip joints through conventional hip arthrocentesis sites under sedation with
dexmedetomidine (dexdomitor, Zoetis, Madrid, Spain). After the injection, the dogs were sent
home and the owners given instructions on the administration of cephalosporin (20 mg/kg/
12h, PO) and omeprazole (0.7 mg/kg/24h, PO) as a prophylactic antibiotic and gastric mucosa
protector, respectively, for 7 days.
Force platform gait analysis
Gait analysis was performed using a single platform mounted in the center of, and level with, a
7-m runway covered by a rubber mat. The mat weight was accounted for by setting to “0 force”
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with the tare button after the platform was covered. All dogs were leash guided at walk over the
force platform by the same handler. Walk velocity was measured by use of a motion sensor
(Pasco, CA, USA) positioned 1 m from the platform.
Five valid trials, at a sampling frequency of 250 Hz, were obtained for each dog. A trial was
considered valid when the limb fully contacted the force platform, and with the dog walking
next to the handler without pulling on the leash. The trial was discarded if the dog was dis-
tracted during the measurement, if the limb struck the edge of the force plate, or if any portion
of the contralateral paw hit the force plate. A member of the research team evaluated the trial
to confirm which limb touched the center of the force platform.
The platform was interfaced with a dedicated computer using DataStudio software (Pasco,
CA, USA), which is specially designed for the acquisition, numerical conversion, and storage of
data. A team member recorded data from both affected limbs at day 0, 30, 90, and 180 post-
treatment; day 0 data also served to determine which limb was more lame in order to use it as
reference of lameness evolution. The obtained peak vertical force (PVF) was expressed in New-
tons (N) and normalized relative to body weight (%BW) to characterize possible improvement
of lameness during treatment with MSCs.
Collagen and HA serum levels
Blood samples were taken by direct jugular venipuncture from all participants in the early
morning immediately before injection (D0), and on days 30, 90, and 180 post-injection. Sera
were obtained after blood centrifugation for 15 minutes at 3,000 rpm to measure canine C2C
and HA. These two biomarkers were measured by commercial ELISA kits (MyBioSource, San
Diego, CA, USA, and Teco Medical, Sissach, Switzerland, respectively). Both assays showed
intra and inter assay precision lower than 15% and coefficients of regression higher than 0.98
after linear dilution.
Statistical analysis
Parameters were estimated by using the free R statistical software (https://www.r-project.org/).
Data were assessed for normality with the Shapiro-Wilk test, and the nonparametric Kruskal-
Wallis and Mann-Whitney U tests were used to compare non-categorical variables at each fol-
low-up time. A repeated measure ANOVA with a post-hoc Tukey test or related-samples Wil-
coxon signed rank test was used to evaluate differences between times, as necessary. For
correlation between biomarkers and PVF, Pearson correlation coefficient was used.
Results
The animals had a mean body weight of 52.8 ± 3.4 kg and a mean age of 4.7± 1.2 years.
PVF
The mean value for walking velocity of dogs was 1.6 ± 0.5 m/sec. No significant difference in
walking velocity existed between dogs (P = 0.063).
Mean values of PVF are summarized in Table 1. Results showed that differences in PVF
between D0 and the other periods were all significant (P< 0.001). D30 and D180 also showed
significant differences (P< 0.001). Fig 1 shows how PVF values increased progressively, with
higher improvement within the first 30 days(Fig 1). At D180, PVF values were similar to those
previously reported for sound dogs of the same breed (about 48% BW) [20].
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C2C. Mean values of serum C2C are summarized in Table 2. Results showed that differ-
ences between D0 and D180 and between D30 and D180 were significant (P = 0.041 and 0.014,
respectively). The graph in Fig 2 shows how serum levels decreased(Fig 2).
HA. Mean values of serum HA are summarized in Table 3. Differences between D0 and all
other periods were all significant (P< 0.049). Differences between D90 and D180 were also sig-
nificant (P = 0.022). The graph in Fig 3 shows how serum levels increased (Fig 3).
Correlation
A significant inverse correlation (Pearson r = -071) was found between C2C and PVF
(P = 0.008) (Fig 4). However, a positive association between HA and PVF (Pearson r = 0.477)
could be demonstrated (P = 0.011) (Fig 5).
Table 1. PVF expressed asmean ± SD of %BW.
D0 D30 D90 D180
D0 43.27 ± 1.04 P ˂ 0.001 P ˂ 0.001 P ˂ 0.001
D30 48.5 ± 1.85 P = 0.19 P ˂ 0.001
D90 49.47 ± 1.62 P = 0.77
D180 51.23 ± 2.89
D = day. P < 0.05 is considered statistically significant. Unit = Newton.
doi:10.1371/journal.pone.0149472.t001
Fig 1. Scatterplot showing evolution of PVF after treatment at the 180-day follow-up period. Each color
corresponds to one dog. The graph shows how PVF increases in terms of percent body weight (%BW). The Y
axis minimumwas set at 40% BW. Unit = Newton.
doi:10.1371/journal.pone.0149472.g001
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Discussion
In this study, the correlation between serum levels of C2C and HA biomarkers and objective
evolution of PVF values in dogs with hip OA before and after treatment has been
demonstrated.
The overproduction of destructive substances and inflammation mediators in OA give rise
to a balance in favor of articular cartilage catabolism [26]. The collagen framework becomes
disrupted, and the proteoglycans content of the articular cartilage diminishes. Proteoglycan
fragments and the breakdown products of type II collagen, are liberated in increased concen-
trations to reach the synovial fluid and the serum [17,27]. All of these variations could be mon-
itored by measuring the molecules derived from this synthesis and degradation in serum [3].
The diagnosis of OA is generally based on clinical and radiographic changes that occur in
the later stages of the disease; this technique shows the bone texture at a given moment. Radiol-
ogy has been widely used for its ease of availability and accessibility, although there is contro-
versy as to its utility as a diagnostic method for evaluating responses to different treatments
[28]. For this reason, biomarkers could aid in monitoring disease status, predicting disease pro-
gression, and studying the effects of novel therapeutic interventions in a variety of joint diseases
[7].
Table 2. Serum levels (ng/ml) of C2C expressed as mean ± SD.
D0 D30 D90 D180
D0 91.51 ± 45.25 P = 0.724 P = 0.169 P = 0.041
D30 82.94 ± 40.88 P = 0.353 P = 0.014
D90 66.14 ± 28.08 P = 0.158
D180 41.91 ± 25.51
P < 0.05 is considered statistically significant.
doi:10.1371/journal.pone.0149472.t002
Fig 2. Scatterplot showing decrease of C2C serum levels (ng/ml) after treatment at the 180-day follow-
up period. Each color corresponds to one dog.
doi:10.1371/journal.pone.0149472.g002
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There is controversy in the usefulness of C2C as a biomarker in OA; while some authors
determined an increase of C2C serum concentrations in human and dog patients suffering
from injured joints [4,10,12,29], other authors suggested that collagenase-specific degradation
of type II collagen in articular cartilage may not be involved, at least in early stages of naturally
occurring OA [30]. In our study, the results show that after one intraarticular injection of MSC
+ PRGF, a concurrent decrease in C2C level and OA improvement occurred, as objectively
measured by force plate analysis.
Although previous studies have suggested that HA may be used as a biomarker in OA dogs
[17,18], some controversy exists between those reports of elevation in HA in relation to the
degree of OA in humans [6,13] and dogs [14,15], and those performed in dogs in which the
opposite seems to occur: levels of HA in OA animals were lower than those in healthy animals
and seemed to increase when animals improved with physical or surgical therapy [16,18,19].
Our results are consistent with these findings in that the treated dogs’ HA serum levels were
significantly higher compared with D0 at 1, 3, and 6 months follow-up after the MSC + PRGF
intraarticular injection. However, although our results showed statistical correlation with PVF
values, we observed a high variability. These results could have several possible explanations:
the first one could be the diurnal-related changes in this marker that have been previously
Table 3. Serum levels (ng/ml) of HA expressed asmean ± SD.
D0 D30 D90 D180
D0 40.87 ± 32.1 P = 0.030 P = 0.049 P = 0.011
D30 98.40 ± 63.23 P = 0.066 P = 0.49
D90 74.45 ± 45.74 P = 0.022
D180 112.88 ± 55.21
P < 0.05 is considered statistically significant.
doi:10.1371/journal.pone.0149472.t003
Fig 3. Scatterplot showing increase of HA serum levels (ng/ml) after treatment at the 180-day follow-
up period. Each color corresponds to one dog.
doi:10.1371/journal.pone.0149472.g003
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Fig 4. Scatterplot showing correlation between C2C and PVF at the 180-day follow-up period. Each
symbol represents the values of any individual dog at the same checking period. The solid line represents the
trend line. Dotted lines represent the 95% confidence interval. The Y axis minimumwas set at 35% BW.
doi:10.1371/journal.pone.0149472.g004
Fig 5. Scatterplot showing correlation between HA and PVF at the 180-day follow-up period. Each
symbol represents the values of any individual dog at the same checking period. The solid line represents the
trend line. Dotted lines represent the 95% confidence interval. The Y axis minimumwas set at 35% BW.
doi:10.1371/journal.pone.0149472.g005
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described [31]; to account for such changes, comparisons should be performed only when HA
levels are measured in the same hour. Secondly, food quantity and characteristics seem to sig-
nificantly affect HA levels [32]; therefore, comparisons should be made only in patients sub-
mitted to the same feeding protocol and the same period of fast. Third, HA levels in OA could
behave differently when different species or even different breeds are compared. In addition,
some pathologies, especially those with hepatic damage, have been demonstrated to alter
serum HA levels [15,33]; therefore, HA studies should include animals with normal hemato-
logical and blood biochemical profiles.
In summary, HA serum levels in dogs could not be modified only by structural or functional
changes in joints, although these levels showed a significant elevation when condition
improved; further research should clarify the role of HA as an indicator of functional status in
dogs to determine if HA behaves in the same manner in dogs as in humans [13]. This aim
could be achieved by using a larger study group with the same research protocol (breed, food,
time of blood samples, etc.).
Based in our results, the C2C and HA biomarkers might be a promising way to objectively
measure improvement after OA treatment in canine joints. An association was seen between
decreased C2C and increased HA serum levels and improvement in lameness.
Conclusion
Based on the results from the current study, C2C and HA serum concentration are adequate
and objective biomarkers for testing the limb functionality of treated OA joints in dogs.
Supporting Information
S1 ARRIVE Checklist. ARRIVE guidelines.
(PDF)
Acknowledgments
The authors thank Thomas Michael Oxlee and Misty Bailey for translation and editing.
Author Contributions
Conceived and designed the experiments: RC MGB JMC. Performed the experiments: JMV BC
JMC. Analyzed the data: JS JMDMG. Contributed reagents/materials/analysis tools: AT JJC.
Wrote the paper: JMVMR GS.
References
1. Juni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract
Res Clin Rheumatol. 2006; 20: 721–740. PMID: 16979535
2. Malek S, Sample SJ, Schwartz Z, Nemke B, Jacobson PB, Cozzi EM, et al. Effect of analgesic therapy
on clinical outcomemeasures in a randomized controlled trial using client-owned dogs with hip osteoar-
thritis. BMC Vet Res. 2012; 8: 185. doi: 10.1186/1746-6148-8-185 PMID: 23035739
3. Ramonda R, Lorenzin M, Modesti V, Campana C, Ortolan A, Frallonardo P, et al. Serological markers
of erosive hand osteoarthritis. Eur J Intern Med. 2013; 24: 11–15. doi: 10.1016/j.ejim.2012.10.002
PMID: 23102569
4. Goranov NV. Serummarkers of lipid peroxidation, antioxidant enzymatic defense, and collagen degra-
dation in an experimental (Pond-Nuki) canine model of osteoarthritis. Vet Clin Pathol. 2007; 36: 192–
195. PMID: 17523095
5. Bedson J, Croft P. The discordance between clinical and radiographic knee osteoarthritis: a systematic
search and summary of the literature. BMCMusculoskelet Disord. 2008; 9: 116. doi: 10.1186/1471-
2474-9-116 PMID: 18764949
Biomarkers in Dog Osteoarthritis
PLOS ONE | DOI:10.1371/journal.pone.0149472 February 17, 2016 9 / 11
6. Sasaki E, Tsuda E, Yamamoto Y, Iwasaki K, Inoue R, Takahashi I, et al. Serum hyaluronan levels
increase with the total number of osteoarthritic joints and are strongly associated with the presence of
knee and finger osteoarthritis. Int Orthop. 2013; 37: 925–930. doi: 10.1007/s00264-013-1849-x PMID:
23508866
7. Lotz M, Martel-Pelletier J, Christiansen C, Brandi M, Bruyère O, Chapurlat R, et al. Value of biomarkers
in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013; 72:1756–1763. doi: 10.1136/
annrheumdis-2013-203726 PMID: 23897772
8. Garnero P, Delmas P. Biomarkers in osteoarthritis. Curr Opin Rheumatol. 2003; 15: 641–646. PMID:
12960494
9. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in
vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved
by collagenases. J Immunol Methods. 2004; 294: 145–153. PMID: 15637808
10. Chu Q, Lopez M, Hayashi K, Ionescu M, Billinghurst RC, Johnson KA, et al. Elevation of a collagenase
generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of
joint instability in the dog. Osteoarthritis Cartilage. 2002; 10: 662–669. PMID: 12479389
11. Prink A, Hayashi K, Kim SY, Kim J, Kapatkin A. Evaluation of a collagenase generated osteoarthritis
biomarker in the synovial fluid from elbow joints of dogs with medial coronoid disease and unaffected
dogs. Vet Surg. 2010; 39: 65–70. doi: 10.1111/j.1532-950X.2009.00604.x PMID: 20210947
12. Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR. Analysis of cartilage biomarkers in the early phases
of canine experimental osteoarthritis. Arthritis Rheum. 2004; 50: 543–552. PMID: 14872497
13. Ishijima M, Watari T, Naito K, Kaneko H, Futami I, Yoshimura-Ishida K, et al. Relationships between
biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of
pain in early knee osteoarthritis. Arthritis Res Ther. 2011; 13: 22.
14. Thonar EJ, Masuda K, Lenz ME, Hauselmann HJ, Kuettner KE, Manicourt DH. Serummarkers of sys-
temic disease processes in osteoarthritis. J Rheumatol Suppl. 1995; 43: 68–70. PMID: 7752142
15. Arican M, Carter SD, May C, Bennett D. Hyaluronan in canine arthropathies. J Comp Pathol. 1994;
111: 185–195. PMID: 7806704
16. Nganvongpanit K, Itthiarbha A, Ong-Chai S, Kongtawelert P. Evaluation of serum chondroitin sulfate
and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia. J Vet Sci. 2008; 9: 317–325.
PMID: 18716453
17. Leipold HR, Goldberg RL, Lust G. Canine serum keratan sulfate and hyaluronate concentrations. Rela-
tionship to age and osteoarthritis. Arthritis Rheum. 1989; 32: 312–321. PMID: 2522784
18. Budsberg SC, Lenz ME, Thonar EJ. Serum and synovial fluid concentrations of keratan sulfate and
hyaluronan in dogs with induced stifle joint osteoarthritis following cranial cruciate ligament transection.
Am J Vet Res. 2006; 67: 429–432. PMID: 16506904
19. Nganvongpanit K, Tanvisut S, Yano T, Kongtawelert P. Effect of Swimming on Clinical Functional
Parameters and Serum Biomarkers in Healthy and Osteoarthritic Dogs. ISRN Veterinary Science 2014
Jan 9. 459809. doi: 10.1155/2014/459809
20. Vilar JM, Batista M, Morales M, Santana A, Cuervo B, Rubio M, et al. Assessment of the effect of intra-
articular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a
double blinded force platform analysis. BMC Vet Res. 2014; 10: 143. doi: 10.1186/1746-6148-10-143
PMID: 24984756
21. Vilar JM, Morales M, Santana A, Spinella G, Rubio M, Cuervo B, et al. Controlled, blinded force platform
analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells
associated to PRGF-Endoret in osteoarthritic dogs. BMC Vet Res. 2013; 9: 131. doi: 10.1186/1746-
6148-9-131 PMID: 23819757
22. Piermattei D, Flo G, DeCamp C. Hip joint. In: Fathman L, editor. Brinker, Piermattei and Flo’s handbook
of small orthopedics and fracture repair. Saunders; 2006. pp. 461–511.
23. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for
defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy. 2006; 8: 315–317. PMID: 16923606
24. Cuervo B, Rubio M, Sopena J, Dominguez JM, Vilar J, Morales M, et al. Hip osteoarthritis in dogs: a ran-
domized study using mesenchymal stem cells from adipose tissue and plasma rich in growth factors.
Int J Mol Sci. 2014; 15: 13437–13460. doi: 10.3390/ijms150813437 PMID: 25089877
25. Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors
(PRGF) in different medical fields. Biomaterials. 2007; 28: 4551–6450. PMID: 17659771
26. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in
the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011; 7: 33–42. doi: 10.1038/nrrheum.
2010.196 PMID: 21119608
Biomarkers in Dog Osteoarthritis
PLOS ONE | DOI:10.1371/journal.pone.0149472 February 17, 2016 10 / 11
27. Hegemann N, Kohn B, Brunnberg L, Schmidt MF. Biomarkers of joint tissue metabolism in canine oste-
oarthritic and arthritic joint disorders. Osteoarthritis Cartilage. 2002;. 10: 714–721. PMID: 12202124
28. Hirvasniemi J, Thevenot J, Immonen V, Liikavainio T, Pulkkinen P, Jämsä T, et al. Quantification of dif-
ferences in bone texture from plain radiographs in knees with and without osteoarthritis. Osteoarthritis
Cartilage. 2014;. 22: 1724–1731. doi: 10.1016/j.joca.2014.06.021 PMID: 25278081
29. Kumahashi N, Swärd P, Larsson S, Lohmander LS, Frobell R, Struglics A. Type II collagen C2C epitope
in human synovial fluid and serum after knee injury—associations with molecular and structural mark-
ers of injury. Osteoarthritis Cartilage. 2015 Apr 29. pii: S1063-4584(15)01142-5. doi: 10.1016/j.joca.
2015.04.022
30. Hayashi K, Kim SY, Lansdowne JL, Kapatkin A, Déjardin LM. Evaluation of a collagenase generated
osteoarthritis biomarker in naturally occurring canine cruciate disease. Vet Surg. 2009; 38: 117–121.
doi: 10.1111/j.1532-950X.2008.00446.x PMID: 19152626
31. Gordon CD, Stabler TV, Kraus VB. Variation in osteoarthritis biomarkers from activity not food con-
sumption. Clin Chim Acta. 2008. Dec. doi: 10.1016/j.cca.2008.07.031
32. Garnero P, Gourley I, Mareau E, Durn B, Hickey L, Cohen S. Biological variability of biochemical mark-
ers of bone, cartilage, and synovial metabolism in patients with knee osteoarthritis: effect of food intake.
Osteoarthritis Cartilage. 2007; 15: 68.
33. Seki M, Asano K, Sakai M, Kanno N, Teshima K, Edamura K, et al. Serum hyaluronic acid in dogs with
congenital portosystemic shunts. J Small Anim Pract. 2010; 51: 260–263. doi: 10.1111/j.1748-5827.
2010.00934.x PMID: 20402843
Biomarkers in Dog Osteoarthritis
PLOS ONE | DOI:10.1371/journal.pone.0149472 February 17, 2016 11 / 11
